地诺孕素治疗子宫腺肌症痛经患者的临床效果及其作用机制研究  

Study on the clinical efficacy of dienogest in treating patients with adenomyosis-associated dysmenorrhea and its mechanism

作　　者：林燕丹 潘琦文[1] 李建湘[1] LIN Yandan;PAN Qiwen;LI Jianxiang(Department of Gynecology,Hechi People’s Hospital,Hechi Hospital,the First Affiliated Hospital of Guangxi Medical University,Guangxi,Hechi 547000,China)

机构地区：[1]广西壮族自治区河池市人民医院、广西医科大学第一附属医院河池医院妇科,广西河池547000

出　　处：《中国医药科学》2024年第2期96-98,102,共4页China Medicine And Pharmacy

摘　　要：目的探讨地诺孕素治疗子宫腺肌症痛经患者的临床效果及其作用机制。方法选取2019年1月至2020年12月河池市人民医院收治的200例子宫腺肌症痛经患者,按随机数表法分为对照组(n=100)和观察组(n=100)。对照组给予孕三烯酮治疗,观察组给予地诺孕素治疗,两组均持续治疗3个月经周期。比较两组治疗前后月经量、视觉模拟评分(VAS)、子宫肌瘤/腺肌病症状(UFS)和生活质量(QOL)评分以及肿瘤坏死因子-α(TNF-α)水平。结果治疗后,两组月经量和VAS评分较治疗前均明显降低,且观察组低于对照组(P<0.05);两组UFS评分较治疗前明显降低,QOL评分较治疗前明显升高,且观察组UFS评分低于对照组,QOL评分高于对照组(P<0.05);两组血清TNF-α水平较治疗前均明显降低,且观察组低于对照组(P<0.05)。结论地诺孕素治疗子宫腺肌症痛经疗效确切,能有效改善患者临床症状,明显提高其生活质量,其作用机制可能与调节血清中TNF-α的表达有关。Objective To investigate the clinical efficacy of dienogest in treating patients with adenomyosisassociated dysmenorrhea and its mechanism.Methods A total of 200 patients with dysmenorrhea in Hechi People’s Hospital from January 2019 to December 2020 were divided into control group(n=100)and observation group(n=100)according to the random number table method.The control group was treated with gestrinone and the observation group was treated with dienogest,and both groups were treated continuously for 3 menstrual cycles.The menstrual volume,visual analogue score(VAS),uterine fibroid/adenomyosis symptoms(UFS)and quality of life(QOL)scores,and tumor necrosis factor-α(TNF-α)levels before and after treatment were compared between the two groups.Results After treatment,menstrual volume and VAS scores were significantly lower in both groups than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).UFS scores were significantly lower and QOL scores were significantly higher in both groups after treatment than those before treatment,and UFS scores were lower and QOL scores were higher in the observation group than those in the control group(P<0.05).Serum TNF-α levels were significantly lower in both groups after treatment than those before treatment,and those in the observation group was lower than those in the control group(P<0.05).Conclusion Dienogest has definite efficacy in the treatment of adenomyosisassociated dysmenorrhea,and it can effectively improve the clinical symptoms and QOL of the patients.Its mechanism may be related to the regulation of the expression of TNF-α in serum.

关 键 词：子宫腺肌症 痛经 地诺孕素 肿瘤坏死因子-Α 

分 类 号：R711.71[医药卫生—妇产科学]